Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis — Probabli.AI
AI-powered analysis for REGN (Regeneron Pharmaceuticals, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
← Healthcare Stocks
Last price: $759.05 · Market cap: $80.0B · AI outlook: Bullish
Regeneron Pharmaceuticals, Inc. demonstrates strong growth potential driven by a diversified and innovative portfolio, strategic partnerships, and a history of outperforming earnings expectations, despite facing some regulatory and industry-specific challenges. The 1-year, 5-year, and 10-year projections indicate substantial bullish prospects, supported by the company's ability to secure FDA…
Probabilistic 1-Year Outlook
- Bull 45% · Neutral 35% · Bear 20%
- 1-year price estimates — P10: $500 / P50: $820 / P90: $950
- Regeneron's positive catalysts, including strategic collaborations and FDA approvals, are expected to drive near-term growth. Supply chain challenges and regulatory delays pose some risks. Analysts are optimistic with a…
5-Year Outlook
- Bull 55% · Neutral 30% · Bear 15%
- 5-year price estimates — P10: $300 / P50: $1,200 / P90: $2,400
SWOT Highlights
- Strength: Strong innovative pipeline
- Strength: Collaborations with key players in biotechnology
- Risk: Dependence on specific flagship products
- Risk: Supply chain and regulatory challenges
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
24 Wall Street analysts rate REGN a BUY with a mean price target of $819.54. Regeneron Pharmaceuticals, Inc. currently pays a dividend with a yield of approximately 0.50%.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
REGN forecast details · REGN sentiment details
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.